Evidence map›Paper›PMID 35255932›Full record

ReviewJournal of translational medicine2022

Microbiota medicine: towards clinical revolution.

Prisca Gebrayel, Carole Nicco, Souhaila Al Khodor, Jaroslaw Bilinski, Elisabetta Caselli, Elena M Comelli, Markus Egert, Cristina Giaroni, Tomasz M Karpinski, Igor Loniewski and 11 more

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05603403 (Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms), which is not on this map. Cited by 138 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 5 pooled it
21.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05603403 phase4completednot on this map

Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

TypeinterventionalSponsorAzidus BrasilRan2022 to 2023Enrolled150ConditionsSigns and Symptoms, DigestiveArmsProbiatop, Placebo
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 5 syntheses or guidelines pooled it, 252 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 16 institutions in 5 countries.

Prisca GebrayelInternational Society of Microbiota, Tokyo, Japan.
Carole NiccoDepartment Endocrinology, Metabolism and Diabetes, Faculté de Médecine Cochin-Port Royal, Université de Paris, INSERM U1016, Institut Cochin, 24 Rue du Faubourg St Jacques, 75014, Paris, France.
Souhaila Al KhodorMaternal and Child Health Department, Research Branch, Sidra Medicine, Doha, Qatar.
Jaroslaw BilinskiMedical University of Warsaw, Warsaw, Poland.
Elisabetta CaselliUniversity of Ferrara, Ferrara, Italy.
Elena M ComelliUniversity of Toronto, Toronto, Canada.
Markus EgertFurtwangen University, Furtwangen, Germany.
Cristina GiaroniDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Tomasz M KarpinskiPoznań University of Medical Sciences, Poznań, Poland.
Igor LoniewskiPomeranian Medical University, Szczecin, Poland.
Agata MulakWroclaw Medical University, Wroclaw, Poland.
Julie ReygnerUniversité Paris Descartes, Paris, France.
Paulina SamczukClinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
Matteo SerinoIRSD, Université de Toulouse, INSERM, INRAE, ENVT, UPS, Toulouse, France.
Mariusz SikoraNational Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Annalisa TerranegraMaternal and Child Health Department, Research Branch, Sidra Medicine, Doha, Qatar.
Marcin UfnalMedical University of Warsaw, Warsaw, Poland.
Romain VillegerUniversity of Clermont Auvergne, Clermont-Ferrand, France.
Chantal PichonCenter for Molecular Biophysics CNRS UPR 4301, University of Orléans, Orléans, France.
Peter KonturekTeaching Hospital of the University of Jena, Jena, Germany.
Marvin EdeasDepartment Endocrinology, Metabolism and Diabetes, Faculté de Médecine Cochin-Port Royal, Université de Paris, INSERM U1016, Institut Cochin, 24 Rue du Faubourg St Jacques, 75014, Paris, France. marvin.edeas@inserm.fr.ORCID 0000-0001-7127-5229
Inserm · FRMedical University of Warsaw · PLDélégation Paris 5 · FRFurtwangen University · DEJena University Hospital · DEMedical University of Białystok · PLNational Institute of Geriatrics, Rheumatology and Rehabilitation · PLPomeranian Medical University · PLPoznan University of Medical Sciences · PLUniversité Clermont Auvergne · FRUniversité d'Orléans · FRUniversité Toulouse III - Paul Sabatier · FRUniversity of Ferrara · ITUniversity of Insubria · ITUniversity of Toronto · CAWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human gastrointestinal tract is inhabited by the largest microbial community within the human body consisting of trillions of microbes called gut microbiota. The normal flora is the site of many physiological functions such as enhancing the host immunity, participating in the nutrient absorption and protecting the body against pathogenic microorganisms. Numerous investigations showed a bidirectional interplay between gut microbiota and many organs within the human body such as the intestines, the lungs, the brain, and the skin. Large body of evidence demonstrated, more than a decade ago, that the gut microbial alteration is a key factor in the pathogenesis of many local and systemic disorders. In this regard, a deep understanding of the mechanisms involved in the gut microbial symbiosis/dysbiosis is crucial for the clinical and health field. We review the most recent studies on the involvement of gut microbiota in the pathogenesis of many diseases. We also elaborate the different strategies used to manipulate the gut microbiota in the prevention and treatment of disorders. The future of medicine is strongly related to the quality of our microbiota. Targeting microbiota dysbiosis will be a huge challenge.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaProbioticsDysbiosisGastrointestinal TractHumansPrebioticsPrebioticsBuilt environment microbiomeDysbiosisFecal microbiota transplantMetabolic syndromeMetabolitesmiRNAsOral microbiotaPrebioticsProbiotics

Identifiers

PMID35255932
PMCPMC8900094
OpenAlexW4220782264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.